Clinical responses in patients with advanced colorectal cancer to a dendritic cell based vaccine

Oncology Reports

Volumn 20, Issue 6, 2008, Pages 1305-1311

  Burgdorf, Stefan K ^a   Fischer, Anders ^a   Myschetzky, Peter S ^a   Munksgaard, Signe B ^a   Zocca, Mai Britt ^b   Claesson, Mogens H ^c   Rosenberg, Jacob ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b DanDrit Biotech A/S   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cancer vaccines; Colorectal cancer; Dendritic cells; Quality of life

Indexed keywords

DENDRITIC CELL VACCINE; CANCER VACCINE; TUMOR ANTIGEN;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CELL LYSATE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HUMAN; MALE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; SHORT FORM 36; SURVIVAL TIME; BIOPSY; COLORECTAL TUMOR; DENDRITIC CELL; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; QUESTIONNAIRE; TIME;

ADULT; AGED; ANTIGENS, NEOPLASM; BIOPSY; CANCER VACCINES; COLORECTAL NEOPLASMS; DENDRITIC CELLS; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; TIME FACTORS;

EID: 59249097938     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000145     Document Type: Article

References (25)

1. Jemal A, Murray T, Ward E, et al: Cancer statistics, 2005. CA Cancer J Clin 55: 10-30, 2005.
2. Goldberg RM: Advances in the treatment of metastatic colorectal cancer. Oncologist 10 (Suppl. 3): 40-48, 2005.
3. Zampino MG, Magni E, Massacesi C, et al: First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer. Cancer 110: 752-758, 2007.
4. Ju JH, Chang SC, Wang HS, et al: Changes in disease pattern and treatment outcome of colorectal cancer: a review of 5,474 cases in 20 years. Int J Colorectal Dis 22: 855-862, 2007.
5. Arndt V, Merx H, Stegmaier C, Ziegler H and Brenner H: Restrictions in quality of life in colorectal cancer patients over three years after diagnosis: a population based study. Eur J Cancer 42: 1848-1857, 2006.
6. McWilliams RR, Goetz MP, Morlan BW, et al: Phase II trial of oxaliplatin/irinotecan/5-fluorouracil/leucovorin for metastatic colorectal cancer. Clin Colorectal Cancer 6: 516-521, 2007.
7. Nakata B, Sowa M, Tsuji A, et al: Continuous infusion of 5-fluorouracil with versus without low-dose, consecutive administration of cisplatin in advanced colorectal cancer. A prospective randomized phase II study. J Exp Clin Cancer Res 26: 51-60, 2007.
8. Rosenberg SA, Yang JC and Restifo NP: Cancer immunotherapy: moving beyond current vaccines. Nat Med 10: 909-915, 2004.
9. Huber CH and Wolfel T: Immunotherapy of cancer: from vision to standard clinical practice. J Cancer Res Clin Oncol 130: 367-374, 2004.
10. Cranmer LD, Trevor KT and Hersh EM: Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother 53: 275-306, 2004.
11. Nagorsen D and Thiel E: Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin Cancer Res 12: 3064-3069, 2006.
12. Ridgway D: The first 1000 dendritic cell vaccinees. Cancer Invest 21: 873-886, 2003.
13. Rosenberg SA: Progress in the development of immunotherapy for the treatment of patients with cancer. J Intern Med 250: 462-475, 2001.
14. Burgdorf SK, Fischer A, Claesson MH, et al: Vaccination with melanoma lysate-pulsed dendritic cells, of patients with advanced colorectal carcinoma: report from a phase I study. J Exp Clin Cancer Res 25: 201-206, 2006.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
16. Bjorner JB, Thunedborg K, Kristensen TS, Modvig J and Bech P: The Danish SF-36 Health Survey: translation and preliminary validity studies. J Clin Epidemiol 51: 991-999, 1998.
17. Ware JE Jr and Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30: 473-483, 1992.
18. Gerhardt A, Usener D, Keese M, et al: Tissue expression and sero-reactivity of tumor-specific antigens in colorectal cancer. Cancer Lett 208: 197-206, 2004.
19. De GA, Figer A, Seymour M, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18: 2938-2947, 2000.
20. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343: 905-914, 2000.
21. Liang W, Wang H, Sun TM, et al: Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. World J Gastroenterol 9: 495-498, 2003.
22. Klein G and Klein E: Surveillance against tumors - is it mainly immunological? Immunol Lett 100: 29-33, 2005.
23. Yu P, Lee Y, Wang Y, et al: Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J Immunol 179: 1960-1968, 2007.
24. Reiman JM, Kmieciak M, Manjili MH and Knutson KL: Tumor immunoediting and immunosculpting pathways to cancer progression. Semin Cancer Biol 17: 275-287, 2007.
25. Leen AM, Rooney CM and Foster AE: Improving T cell therapy for cancer. Annu Rev Immunol 25: 243-265, 2007.